ReviewFrontiers in oncology2025
Diagnostic utility of MRI-based convolutional neural networks in soft tissue sarcomas: a mini-review.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This review assesses the diagnostic performance of MRI-based convolutional neural networks for identifying and grading soft tissue sarcomas, evaluating therapy responses, and assessing the risk for metastases and recurrences. Methods: Electronic databases, specifically PubMed/MEDLINE and Google Scholar, were diligently scoured for studies that delved into the intersection of convolutional neural networks, soft tissue sarcomas, and MRI. Three topics were included: 1) differentiating and grading soft tissue sarcomas, 2) assessing therapy response, and 3) predicting metastases and recurrences. Results: This review included 12 articles. Seven articles investigated the differentiation and grading of soft tissue sarcomas. Sensitivity for that issue ranged from 0.85 to 0.95, specificity from 0,33 to 1, and the area under the curve (AUC) from 0.74 to 0.96. Three articles investigated therapy responses, and two discussed metastasis and recurrence prediction. Only one article out of the five articles above presented accurate diagnostic values. That article examined the prediction of lung metastases and demonstrated a sensitivity of 0.47, a specificity of 0.97, and an AUC of 0.83. Conclusion: AI applications using CNNs demonstrated robust capabilities in differentiating and grading soft tissue sarcomas using MRI. However, studies on therapy response and prediction of metastases and recurrences are still lacking.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.